EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial

Bochra Sedaki, Alexandre Iat, Sami Benachour, Michael Loschi, Karine Risso, Ghada Abichou, Corinne Ferrero-Vacher, Neila De Pooter, Joy Mouanes-Abelin, Berengere Dadone-Montaudie, Thomas Cluzeau

Acta Haematologica · 2025

DOI: 10.1159/000548334 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Acta Haematologica, 2025. Verfasst von Bochra Sedaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology department, Nice University Hospital, Nice, France. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Azacitidine + venetoclax is a new standard of care for acute myeloid leukemia not eligible for intensive chemotherapy. This combination is associated with hematological toxicities and some drug interactions. Real-world studies have shown a decrease in results and outcomes when compared to the VIALE-A study.

Methods

We report here our single-center experience using AZA + VEN, rigorously following management guidelines from the VIALE-A study, applied to a real-life population.

Results

Forty-two AML patients were analyzed. The complete remission (CR)/CR with incomplete recovery (CRi)/MLFS rate was 73.8% after 1 cycle with 51% CR/CRi and 80.9% after 2 cycles. Median overall survival was 18 months (95% CI, 10.3–25.7). Our retrospective study showed that rigorous use of AZA + VEN in a real-world setting was associated with results close to clinical trial observations.

Conclusion

We showed the need to rigorously follow AZA+VEN dosage but also toxicity guidelines and practice recommendations edited in the clinical trial even in the real world.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsHumansBridged Bicyclo Compounds, HeterocyclicSulfonamidesAzacitidineAgedFemaleMiddle AgedMaleRetrospective StudiesAdultPractice Guidelines as TopicRemission Induction

Stichwörter der Autor:innen

Acute myeloid leukemiaAzacitidineReal worldVenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesAzacitidine

Autor:innen und Institutionen

  • Hematology department, Nice University Hospital, Nice, France.
  • INSERM U1065, Mediterranean Center of Molecular Medecine, Nice, France.
  • Infectiology department, Nice University Hospital, Nice, France.
  • Cytology department, Nice University Hospital, Nice, France.
  • Molecular Oncology Department, Nice University Hospital, Nice, France.
  • Hematology department, Nice University Hospital, Nice, France, cluzeau.t@chu-nice.fr.

Zitieren

APA

Sedaki, B., Iat, A., Benachour, S., Loschi, M., Risso, K., Abichou, G., Ferrero-Vacher, C., De Pooter, N., Mouanes-Abelin, J., Dadone-Montaudie, B., & Cluzeau, T. (2025). Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial. Acta Haematologica. https://doi.org/10.1159/000548334

Vancouver

Sedaki B, Iat A, Benachour S, Loschi M, Risso K, Abichou G, et al. Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial. Acta Haematologica. 2025. doi:10.1159/000548334

BibTeX
@article{Sedaki2025,
  author = {Sedaki, Bochra and Iat, Alexandre and Benachour, Sami and Loschi, Michael and Risso, Karine and Abichou, Ghada and Ferrero-Vacher, Corinne and De Pooter, Neila and Mouanes-Abelin, Joy and Dadone-Montaudie, Berengere and Cluzeau, Thomas},
  title = {Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial},
  journal = {Acta Haematologica},
  year = {2025},
  doi = {10.1159/000548334}
}
Kostenlos starten →